"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Descriptor ID |
D005234
|
| MeSH Number(s) |
C06.552.241
|
| Concept/Terms |
Steatohepatitis- Steatohepatitis
- Steatohepatitides
- Steatosis of Liver
- Visceral Steatosis
- Steatoses, Visceral
- Steatosis, Visceral
- Visceral Steatoses
- Liver Steatosis
- Liver Steatoses
- Steatoses, Liver
- Steatosis, Liver
|
Below are MeSH descriptors whose meaning is more general than "Fatty Liver".
Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".
This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 4 | 0 | 4 |
| 2007 | 3 | 1 | 4 |
| 2008 | 3 | 1 | 4 |
| 2009 | 8 | 2 | 10 |
| 2010 | 3 | 5 | 8 |
| 2011 | 7 | 4 | 11 |
| 2012 | 6 | 7 | 13 |
| 2013 | 7 | 5 | 12 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 3 | 4 | 7 |
| 2017 | 3 | 3 | 6 |
| 2018 | 6 | 3 | 9 |
| 2019 | 3 | 0 | 3 |
| 2020 | 3 | 1 | 4 |
| 2021 | 4 | 1 | 5 |
| 2023 | 1 | 1 | 2 |
| 2024 | 6 | 10 | 16 |
| 2025 | 11 | 5 | 16 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fatty Liver" by people in Profiles.
-
Assessment of non-invasive fibrosis scoring systems in pediatric MASLD: A retrospective comparison across healthy, MASLD, and biopsy-staged groups. Clin Chim Acta. 2026 Apr 15; 586:120905.
-
Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation. Hepatol Commun. 2026 Feb 01; 10(2).
-
Evolving burden of metabolic dysfunction-associated steatotic liver disease and its complications in a US nationwide healthcare system. Hepatol Commun. 2026 Jan 01; 10(1).
-
Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease. J Gastrointestin Liver Dis. 2025 Dec 26; 34(4):437-450.
-
The Basics of Metabolic Dysfunction-Associated Steatotic Liver Disease for Cardiologists: Pathophysiology, Diagnosis, and Treatment. J Am Coll Cardiol. 2025 Nov 18; 86(20):1861-1884.
-
Glycerol-3-phosphate activates ChREBP, FGF21 transcription and lipogenesis in citrin deficiency. Nat Metab. 2025 Nov; 7(11):2284-2299.
-
Exposure to a persistent organic pollutant mixture resulted in sex-specific steatotic liver disease: Role of the liver-endocrine axis. Environ Pollut. 2026 Jan 01; 388:127364.
-
Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States. J Med Econ. 2025 Dec; 28(1):1370-1387.
-
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025 Jul 01; 48(7):1057-1082.
-
Call to action-Pediatric MASLD requires immediate attention to curb health crisis. Hepatology. 2025 Nov 01; 82(5):1341-1351.